ALLELE Trademark

Trademark Overview


On Thursday, September 1, 2016, a trademark application was filed for ALLELE with the United States Patent and Trademark Office. The USPTO has given the ALLELE trademark a serial number of 87158961. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 22, 2018. This trademark is owned by Atara Biotherapeutics, Inc.. The ALLELE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Developing pharmaceutical and therapeutic preparations for the treatment of patients with chronic diseases, namely, cancer, kidney disease, diabetics, cachexia, age related sarcopenia, and protein-energy wasting; conducting clinical trials of pharmaceutical and therapeutic preparations for the treatment of patients with chronic diseases, namely, cancer, kidney disease, diabetics, cachexia, age related sarcopenia, and protein-energy wasting; conducting clinical research of the effectiveness of pharmaceutical and therapeutic preparations, namely, by conducting clinical trial on patients with EBV-Associated Post Transplant Lymphoproliferative Disease (EBV-PTLD)
allele

General Information


Serial Number87158961
Word MarkALLELE
Filing DateThursday, September 1, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 22, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 25, 2017

Trademark Statements


Goods and ServicesDeveloping pharmaceutical and therapeutic preparations for the treatment of patients with chronic diseases, namely, cancer, kidney disease, diabetics, cachexia, age related sarcopenia, and protein-energy wasting; conducting clinical trials of pharmaceutical and therapeutic preparations for the treatment of patients with chronic diseases, namely, cancer, kidney disease, diabetics, cachexia, age related sarcopenia, and protein-energy wasting; conducting clinical research of the effectiveness of pharmaceutical and therapeutic preparations, namely, by conducting clinical trial on patients with EBV-Associated Post Transplant Lymphoproliferative Disease (EBV-PTLD)

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 8, 2016
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAtara Biotherapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Party NameAtara Biotherapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Monday, October 22, 2018ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, October 22, 2018ABANDONMENT - NO USE STATEMENT FILED
Thursday, February 22, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 20, 2018EXTENSION 1 GRANTED
Tuesday, February 20, 2018EXTENSION 1 FILED
Tuesday, February 20, 2018TEAS EXTENSION RECEIVED
Tuesday, September 19, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 25, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 25, 2017PUBLISHED FOR OPPOSITION
Wednesday, July 5, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 14, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 13, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 12, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 12, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 12, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 12, 2016NON-FINAL ACTION E-MAILED
Monday, December 12, 2016NON-FINAL ACTION WRITTEN
Saturday, December 10, 2016ASSIGNED TO EXAMINER
Thursday, September 8, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, September 5, 2016NEW APPLICATION ENTERED IN TRAM